3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
17
Neoplasm Metastasis
6
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Colorectal Neoplasms
2
Solid Cancer
1
Salivary Gland Neoplasms
1
Recurrence
1
Pancreatic Neoplasms
1
Neoplasm, Residual
1
HER2-positive Breast Cancer
1
HER2-mutant Non-Small Cell Lung Cancer
1
HER2-Positive Primary Breast Cancer
1
Gastric Adenocarcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Breast Diseases
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Gemcitabine
42
130-nm albumin-bound paclitaxel
26
Albumin-Bound Paclitaxel
18
Irinotecan
16
Oxaliplatin
14
Fluorouracil
14
pembrolizumab
13
Nivolumab
13
Magnetic Resonance Spectroscopy
11
Leucovorin
11
Taxes
10
Specimen Handling
9
Biopsy
9
Cisplatin
8
Capecitabine
7
folfirinox
6
Radiotherapy
6
Carboplatin
6
irinotecan sucrosofate
5
durvalumab
5
Ipilimumab
5
Cyclophosphamide
5
olaparib
4
defactinib
4
Surveys and Questionnaires
4
Standard of Care
4
Radiosurgery
4
Immunoglobulin G
4
Disulfides
4
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Pancreatic Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT04482309
2026-04-09
DPT02
AstraZeneca
Phase 2
Active not recruiting
477 enrolled
1 FDA